Gufic Biosciences (509079) Q3 24/25 earnings summary

Executive summary

• Focus on innovation, market expansion, and high-quality pharmaceutical solutions, with key milestones in critical care, fertility, and specialty segments.

• Indore manufacturing facility commenced production post-validation in October 2024, with scale-up expected in coming quarters and significant future capacity.

• Strategic launches in antibacterial, antifungal, fertility, orthopedics, gastroenterology, and Ayurveda-driven pain management.

• International business expanded with product approvals in Sri Lanka, Lithuania, Ecuador, Kenya, and other markets, enhancing global presence.

• Criticare Division advanced antimicrobial portfolio for multidrug-resistant infections and strengthened hospital partnerships.

Financial highlights

• Q3 FY25 revenue: INR 207.8 crores (₹20,779.39 lakhs), up from INR 201.8 crores (₹20,177.79 lakhs) in Q3 FY24; 9M FY25 revenue: INR 614.8 crores (₹61,801.78 lakhs) vs. INR 616.7 crores (₹61,296.80 lakhs) in 9M FY24.

• Q3 FY25 EBITDA: INR 35.8 crores (margin 17.23%) vs. INR 36.9 crores (margin 18.29%) in Q3 FY24.

• Q3 FY25 PAT: INR 19.4 crores (margin 9.34%), down from INR 22.3 crores (margin 11.05%) in Q3 FY24.

• 9M FY25 PBT: INR 83.6 crores vs. INR 88.6 crores in 9M FY24; 9M FY25 net profit: ₹6,193.00 lakhs, down from ₹6,608.96 lakhs YoY.

• Basic and diluted EPS for Q3 FY25 was ₹1.93, compared to ₹2.23 in Q3 FY24.

Outlook and guidance

• Indore facility expected to reach 25%-30% utilization next year, 50%-60% the following year, with revenue projected at INR 150 crores in 3-5 years and break-even in 4-5 quarters.

• Margin pressure expected for 2-3 quarters due to Indore ramp-up; improvement anticipated post-2026 as utilization increases.

• Focus on scaling up Indore for regulated markets (US/EU), expanding product pipeline, and international expansion.

• Policy amendments and new subsidiary incorporations indicate ongoing alignment with regulatory changes and international expansion.